US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector.
Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare research Jialin Zhang, in a research note on Sunday.
The US Treasury Department was drafting investment...
Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts
Global - Asia
Archived
•
September 21, 2026
•
3 views
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



